R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO [Yahoo! Finance]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Yahoo! Finance
and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), announced today the closing of its $87 million Series B financing round. The company also announced that veteran medical device executive Christopher M. Owens will serve as its new President and Chief Executive Officer. Mr. Owens succeeds the founder Kamal Ramzipoor, who will step into the role of Chief Technology Officer (CTO). The Series B financing was led by affiliates of Deerfield Management with participation from existing shareholders including 415 Capital and a strategic investor. R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD. The funding will also support additional research and development, global regulatory submissions, scale up of manufacturing processes and initial commercialization. MAGNITUDE® is a next generation bioresorbable scaffold with the pot
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Global Companion Diagnostics Industry Research 2024: Epigenomics-Based Companion Diagnostics, Advancing Biomedical Imaging Fueling Growth - Forecast to 2033 [Yahoo! Finance]Yahoo! Finance
- Abbott (ABT) Down 0.4% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
- Polycystic Ovary Syndrome (PCOS) Treatment Global Strategic Research Report 2024-2030: North America and Europe Dominates, Asia-Pacific to Exhibit Fastest Growth [Yahoo! Finance]Yahoo! Finance
- Global Dietary Supplements Market is Anticipated to Reach USD 380.12 Billion at a CAGR of 8.8% CAGR by 2032 - Report by Polaris Market Research (PMR) [Yahoo! Finance]Yahoo! Finance
- Saudi Arabia Baby Food Market Analysis 2017-2023 and Forecast 2024-2029: Nestle, Abbott Laboratories, and Danone Dominated in 2023 [Yahoo! Finance]Yahoo! Finance
ABT
Earnings
- 4/17/24 - Beat
ABT
Sec Filings
- 5/14/24 - Form 4
- 5/10/24 - Form 144
- 5/8/24 - Form 4
- ABT's page on the SEC website